HER2-POSITIVE EARLY BREAST CANCER
Clinical trials for HER2-POSITIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New breast cancer drug combo aims to outperform standard chemo before surgery
Disease control OngoingThis study tests whether a newer drug combination (trastuzumab-deruxtecan, or T-DXd) works better than standard chemotherapy before surgery in people with HER2-positive early breast cancer. About 402 participants will receive either T-DXd or standard chemo, and researchers will c…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: West German Study Group • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New drug cocktail aims to wipe out aggressive breast cancer before surgery
Disease control OngoingThis study tests whether a newer drug, trastuzumab deruxtecan (T-DXd), given alone or with other drugs before surgery, works better than the standard treatment for people with high-risk HER2-positive early breast cancer. About 927 adults will take part. The main goal is to see if…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 19, 2026 11:47 UTC